BACKGROUND: Medication nonadherence is a leading cause of late allograft loss in kidney transplantation (KT). Tacrolimus trough coefficient of variation (CV), measured using the coefficient of variation, is strongly correlated with acute rejection, graft function, and graft loss. OBJECTIVE: The objective of this study was to determine if this mobile health (mHealth) intervention aimed at improving medication adherence in a nonadherent KT population would affect high intrapatient tacrolimus variability. METHODS: A 6-month, prospective, parallel-arm, randomized controlled clinical trial was conducted to determine the effects of an mHealth intervention on tacrolimus CV. Intervention arm participants utilized an electronic medication tray and an mHealth app to monitor home-based adherence. Tailored motivational reinforcement messages were delivered to promote competence for adherence. Tacrolimus CV was measured using a 12-month rolling average, assessed at monthly intervals (6-month intervention period and 6 months after completion of the study); 80 were included, 40 in each arm. RESULTS: At baseline, tacrolimus CV was similar between arms (37% ± 15% intervention, 37% ± 13% control, P = 0.894). Patients randomized to the intervention had a significant reduction in mean 12-month tacrolimus CVs (P = 0.046) and a significant improvement in the proportion achieving low tacrolimus CV (tacrolimus CV < 40%; P = 0.001), as compared with the control arm. CONCLUSION AND RELEVANCE: High tacrolimus CV is a risk factor for acute rejection and graft loss; these results offer the potential promise of improved medication adherence and clinical outcomes through the use of innovative technology.
RCT Entities:
BACKGROUND: Medication nonadherence is a leading cause of late allograft loss in kidney transplantation (KT). Tacrolimus trough coefficient of variation (CV), measured using the coefficient of variation, is strongly correlated with acute rejection, graft function, and graft loss. OBJECTIVE: The objective of this study was to determine if this mobile health (mHealth) intervention aimed at improving medication adherence in a nonadherent KT population would affect high intrapatient tacrolimus variability. METHODS: A 6-month, prospective, parallel-arm, randomized controlled clinical trial was conducted to determine the effects of an mHealth intervention on tacrolimus CV. Intervention arm participants utilized an electronic medication tray and an mHealth app to monitor home-based adherence. Tailored motivational reinforcement messages were delivered to promote competence for adherence. Tacrolimus CV was measured using a 12-month rolling average, assessed at monthly intervals (6-month intervention period and 6 months after completion of the study); 80 were included, 40 in each arm. RESULTS: At baseline, tacrolimus CV was similar between arms (37% ± 15% intervention, 37% ± 13% control, P = 0.894). Patients randomized to the intervention had a significant reduction in mean 12-month tacrolimus CVs (P = 0.046) and a significant improvement in the proportion achieving low tacrolimus CV (tacrolimus CV < 40%; P = 0.001), as compared with the control arm. CONCLUSION AND RELEVANCE: High tacrolimus CV is a risk factor for acute rejection and graft loss; these results offer the potential promise of improved medication adherence and clinical outcomes through the use of innovative technology.
Entities:
Keywords:
Smartphone Medication Adherence Saves Kidneys; coefficient of variation; end-stage renal disease; estimated glomerular filtration rate; kidney transplantation; mobile health; randomized controlled trial; standard of care; time weighted coefficient of variation
Authors: Michael Neipp; Behya Karavul; Steffan Jackobs; Andreas Meyer zu Vilsendorf; Nicolas Richter; Thomas Becker; Anke Schwarz; Juergen Klempnauer Journal: Transplantation Date: 2006-06-27 Impact factor: 4.939
Authors: Henrik Ekberg; Helio Tedesco-Silva; Alper Demirbas; Stefan Vítko; Björn Nashan; Alp Gürkan; Raimund Margreiter; Christian Hugo; Josep M Grinyó; Ulrich Frei; Yves Vanrenterghem; Pierre Daloze; Philip F Halloran Journal: N Engl J Med Date: 2007-12-20 Impact factor: 91.245
Authors: R A Wolfe; V B Ashby; E L Milford; A O Ojo; R E Ettenger; L Y Agodoa; P J Held; F K Port Journal: N Engl J Med Date: 1999-12-02 Impact factor: 91.245
Authors: David J Taber; Zemin Su; James N Fleming; John W McGillicuddy; Maria A Posadas-Salas; Frank A Treiber; Derek Dubay; Titte R Srinivas; Patrick D Mauldin; William P Moran; Prabhakar K Baliga Journal: Transplantation Date: 2017-12 Impact factor: 4.939
Authors: Emilio Rodrigo; David San Segundo; Gema Fernández-Fresnedo; Marcos López-Hoyos; Adalberto Benito; Juan Carlos Ruiz; Maria-Angeles de Cos; Manuel Arias Journal: Transplantation Date: 2016-11 Impact factor: 4.939
Authors: John McGillicuddy; Jessica Chandler; Luke Sox; Martina Mueller; Lynne Nemeth; Prabhakar Baliga; Frank Treiber Journal: JMIR Res Protoc Date: 2019-06-21
Authors: Tatiana M Davidson; John McGillicuddy; Martina Mueller; Brenda Brunner-Jackson; April Favella; Ashley Anderson; Magaly Torres; Kenneth J Ruggiero; Frank A Treiber Journal: J Pers Med Date: 2015-11-17
Authors: Kim H Piburn; Vaka K Sigurjonsdottir; Olafur S Indridason; Lynn Maestretti; Mary Victoria Patton; Anne McGrath; Runolfur Palsson; Amy Gallo; Abanti Chaudhuri; Paul C Grimm Journal: Clin J Am Soc Nephrol Date: 2022-07-26 Impact factor: 10.614
Authors: Lisa Mellon; Frank Doyle; Anne Hickey; Kenneth D Ward; Declan G de Freitas; P Aiden McCormick; Oisin O'Connell; Peter Conlon Journal: Cochrane Database Syst Rev Date: 2022-09-12
Authors: James N Fleming; McLean D Pollock; David J Taber; John W McGillicuddy; Clarissa J Diamantidis; Sharron L Docherty; Eileen T Chambers Journal: Transplant Direct Date: 2022-02-21